Diagnosed with COVID-19 and recovered? Here’s a chance to contribute to pandemic fight
If you’ve been diagnosed with the COVID-19 coronavirus and have recovered, you can help researchers find a potential treatment for the disease.
Read MorePosted by WRAL TechWire | May 15, 2020
If you’ve been diagnosed with the COVID-19 coronavirus and have recovered, you can help researchers find a potential treatment for the disease.
Read MorePosted by WRAL TechWire | May 4, 2020
Grifols is now accepting plasma from volunteer donors who have recovered from the COVID-19 virus at its Raleigh area locations.
Read MorePosted by WRAL News | Apr 24, 2020
Grifols, which has more than 2,000 employees in North Carolina, has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select U.S. cities, none currently in N.C. The University of North Carolina Convalescent Plasma Task Force at the UNC Medical Center in Chapel Hill, however, is collecting convalescent plasma from donors.
Read MorePosted by WRAL TechWire | Apr 9, 2020
Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, will produce and test a potential COVID-19 therapy derived from the blood plasma of patients who have recovered from the coronavirus infection.
Read MorePosted by WRAL TechWire | Mar 5, 2020
In supporting North Carolina’s emergence as a global destination for biotech operations, the state’s higher education institutions have been front and center. Here’s a look at how East Carolina University and Johnston County Community College are helping meet the manpower needs of companies such as Novo Nordisk and Grifols.
Read MorePosted by WRAL TechWire | Jul 10, 2019
Grifols’ product portfolio just got a little larger with U.S. Food and Drug Administration approval of Xembify, a treatment for immune deficiency.
Read MorePosted by WRAL TechWire | May 10, 2019
A significant new arrow has just been added to the quiver of North Carolina’s biomanufacturing global leadership arsenal.
Read MorePosted by WRAL TechWire | Dec 19, 2018
Grifols, the global biotherapeutics company with major operations in North Carolina, announced today that it will begin production of a plasma-derived treatment to battle the Ebola virus for the country of Liberia at its flagship Clayton manufacturing site.
Read MorePosted by WRAL TechWire | Sep 6, 2018
Grifols has received approval from the U.S. FDAfor a new formulation of GamaSTAN, its medicine for treating patients who’ve been exposed to the hepatitis A and measles viruses.
Read More